Armata Pharmaceuticals, Inc.
ARMPCIK 0000921114 · Biological Products, (No Diagnostic Substances) · NYSE
- AmpliPhi Biosciences Corp (until 2019-05-08)
- TARGETED GENETICS CORP /WA/ (until 2011-02-11)
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$164.85M
−818.8% YoY
Q1 May 2026
EPS Diluted (TTM)
−$4.55
−439.3% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$43.94M
Q1 May 2026
Cash
$4.75M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
36.71K sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.